Literature DB >> 3354591

Reversible depression of myocardial performance in hypophosphatemia.

S V Davis1, K K Olichwier, S C Chakko.   

Abstract

Studies of myocardial function in patients with hypophosphatemia have yielded conflicting results. Systolic time intervals were performed in 19 patients during and after the correction of hypophosphatemia; 11 had severe (0.9 +/- 0.15 mg/dL) and eight had moderate (1.4 +/- 0.11 mg/dL) hypophosphatemia. Controls were 14 patients with normal serum phosphorus levels. No patient with hypophosphatemia had clinical congestive heart failure. When hypophosphatemia was corrected, improvement in left ventricular performance was seen only in patients with severe hypophosphatemia (p less than 0.001); in eight patients left ventricular performance was normal during hypophosphatemia but showed significant improvement with its correction (p less than 0.01). Patients with moderate hypophosphatemia showed no significant change. Our results confirm the findings of O'Conner et al, whose study is the only previous one to demonstrate hypophosphatemia-induced myocardial depression in humans. Contradictory results from other studies may be explained by the inclusion of patients with moderate hypophosphatemia and failure to repeat measurements after the correction of hypophosphatemia. We conclude that reversible depression of myocardial performance is seen in hypophosphatemia only when it is severe. In some cases, normal left ventricular performance improves when hypophosphatemia is corrected.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3354591     DOI: 10.1097/00000441-198803000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  8 in total

1.  Re-feeding syndrome and alcoholic cardiomyopathy: A case of interacting diagnoses.

Authors:  Robert J H Miller; Derek Chew
Journal:  J Cardiol Cases       Date:  2016-06-03

Review 2.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms.

Authors:  Michael Freundlich; Gerardo Gamba; Bernardo Rodriguez-Iturbe
Journal:  Pediatr Nephrol       Date:  2020-11-23       Impact factor: 3.714

Review 4.  Phosphate imbalance in patients with heart failure.

Authors:  E C Christopoulou; T D Filippatos; E Megapanou; M S Elisaf; G Liamis
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

5.  High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function.

Authors:  J F Zazzo; G Troché; P Ruel; J Maintenant
Journal:  Intensive Care Med       Date:  1995-10       Impact factor: 17.440

6.  Effect of hypophosphatemia on muscle metabolism after exercise in pigs.

Authors:  L Håglin; B Essén-Gustavsson
Journal:  Acta Vet Scand       Date:  1992       Impact factor: 1.695

7.  Electrolyte and mineral disturbances in septic acute kidney injury patients undergoing continuous renal replacement therapy.

Authors:  Su-Young Jung; Hyunwook Kim; Seohyun Park; Jong Hyun Jhee; Hae-Ryong Yun; Hyoungnae Kim; Youn Kyung Kee; Chang-Yun Yoon; Hyung Jung Oh; Tae Ik Chang; Jung Tak Park; Tae-Hyun Yoo; Shin-Wook Kang; Hajeong Lee; Dong Ki Kim; Seung Hyeok Han
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

Review 8.  Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging.

Authors:  Juan Serna; Clemens Bergwitz
Journal:  Nutrients       Date:  2020-09-30       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.